Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 05 August, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 506414 | NSE: FERMENTA

Fermenta Biotech Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 1, 2025, 3:39 pm

Market Cap 1,065 Cr.
Current Price 362
High / Low 449/219
Stock P/E13.2
Book Value 123
Dividend Yield0.69 %
ROCE23.0 %
ROE24.7 %
Face Value 5.00
PEG Ratio1.19

Quick Insight

Fermenta Biotech Ltd, trading at ₹370, exhibits solid financial health with a market capitalization of ₹1,087 crore and a price-to-earnings (P/E) ratio of 13.5, indicating a potentially undervalued stock relative to its earnings. The company's return on equity (ROE) stands impressively at 24.7%, alongside a return on capital employed (ROCE) of 23%, highlighting effective management and profitability. With an operating profit margin (OPM) of 26% and net profits of ₹76 crore, Fermenta demonstrates operational efficiency. However, the high promoter holding of 62.06% and negligible foreign institutional investment (FIIs) at 0.05% may raise concerns about liquidity. The company’s current cash conversion cycle (CCC) of 139 days suggests potential inefficiencies in inventory management. Overall, while the fundamentals appear strong, investors should weigh the liquidity risks against the promising profitability ratios before making investment decisions.

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Fermenta Biotech Ltd

Competitors of Fermenta Biotech Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Lactose (India) Ltd 140 Cr. 99.1 247/84.327.1 41.70.00 %12.9 %9.75 % 10.0
MPS Pharmaa Ltd 4.72 Cr. 2.47 4.33/2.47 0.570.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 36.6 Cr. 49.4 94.9/45.2 8.730.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 31.7 Cr. 21.6 29.1/13.131.1 6.830.00 %13.5 %11.0 % 10.0
Industry Average19,015.82 Cr1,190.8153.48193.550.32%16.63%15.27%6.18

All Competitor Stocks of Fermenta Biotech Ltd

Quarterly Result

MetricMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
Sales 96929855105825799977895156140
Expenses 7887956586727174927776103103
Operating Profit 1853-101911-142551195337
OPM % 18%5%3%-18%18%13%-24%25%6%1%20%34%26%
Other Income 343-19-82-6353324
Interest 4455654533443
Depreciation 6796666666666
Profit before tax 10-2-8-41-12-29161-6124532
Tax % 21%8%6%-8%373%-0%-0%38%885%-0%6%16%-4%
Net Profit 8-3-8-38-52-2910-7-6113833
EPS in Rs 2.61-0.88-2.75-12.70-1.400.62-9.703.35-2.36-1.983.8712.5411.68

Last Updated: July 18, 2025, 5:05 pm

Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Sales, as of Mar 2025, the value is 140.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Dec 2024) to 140.00 Cr., marking a decrease of 16.00 Cr..
  • For Expenses, as of Mar 2025, the value is 103.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 103.00 Cr..
  • For Operating Profit, as of Mar 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.00 Cr. (Dec 2024) to 37.00 Cr., marking a decrease of 16.00 Cr..
  • For OPM %, as of Mar 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Dec 2024) to 26.00%, marking a decrease of 8.00%.
  • For Other Income, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Dec 2024) to 4.00 Cr., marking an increase of 2.00 Cr..
  • For Interest, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Dec 2024) to 3.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 6.00 Cr..
  • For Profit before tax, as of Mar 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Dec 2024) to 32.00 Cr., marking a decrease of 13.00 Cr..
  • For Tax %, as of Mar 2025, the value is -4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Dec 2024) to -4.00%, marking a decrease of 20.00%.
  • For Net Profit, as of Mar 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Dec 2024) to 33.00 Cr., marking a decrease of 5.00 Cr..
  • For EPS in Rs, as of Mar 2025, the value is 11.68. The value appears to be declining and may need further review. It has decreased from 12.54 (Dec 2024) to 11.68, marking a decrease of 0.86.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:29 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 139142155164302403292376397349335469
Expenses 113126134152209248225293335330307360
Operating Profit 26162112931566683621828110
OPM % 19%11%13%7%31%39%23%22%16%5%8%23%
Other Income 3013961288-20412
Interest 546101421201918211714
Depreciation 1098101212152026282524
Profit before tax 1437-676129435227-51-1083
Tax % 24%67%61%49%28%8%-37%18%44%4%143%8%
Net Profit 1012-946117604315-53-2476
EPS in Rs 2.860.17-0.41-4.1412.2142.7120.2315.465.25-17.36-7.8426.12
Dividend Payout % 29%249%-51%-5%2%1%24%16%23%-7%-16%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-90.00%100.00%-550.00%611.11%154.35%-48.72%-28.33%-65.12%-453.33%54.72%416.67%
Change in YoY Net Profit Growth (%)0.00%190.00%-650.00%1161.11%-456.76%-203.07%20.38%-36.78%-388.22%508.05%361.95%

Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:10%
3 Years:6%
TTM:39%
Compounded Profit Growth
10 Years:67%
5 Years:7%
3 Years:75%
TTM:577%
Stock Price CAGR
10 Years:20%
5 Years:1%
3 Years:23%
1 Year:46%
Return on Equity
10 Years:12%
5 Years:6%
3 Years:4%
Last Year:25%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:18 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 222225141414141415
Reserves 130129128142122246295346358301274348
Borrowings 65718987173209224232239220139115
Other Liabilities 616070758792809496102120137
Total Liabilities 259262288307385551614687707637548614
Fixed Assets 8785168172177178200263299267269227
CWIP 36656542271573545216
Investments 17181518108000300
Other Assets 1189499112193344342367373321277372
Total Assets 259262288307385551614687707637548614

Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
  • For Reserves, as of Mar 2025, the value is 348.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2024) to 348.00 Cr., marking an increase of 74.00 Cr..
  • For Borrowings, as of Mar 2025, the value is 115.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 139.00 Cr. (Mar 2024) to 115.00 Cr., marking a decrease of 24.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 137.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 120.00 Cr. (Mar 2024) to 137.00 Cr., marking an increase of 17.00 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 614.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 548.00 Cr. (Mar 2024) to 614.00 Cr., marking an increase of 66.00 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 227.00 Cr.. The value appears to be declining and may need further review. It has decreased from 269.00 Cr. (Mar 2024) to 227.00 Cr., marking a decrease of 42.00 Cr..
  • For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 14.00 Cr..
  • For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 372.00 Cr.. The value appears strong and on an upward trend. It has increased from 277.00 Cr. (Mar 2024) to 372.00 Cr., marking an increase of 95.00 Cr..
  • For Total Assets, as of Mar 2025, the value is 614.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2024) to 614.00 Cr., marking an increase of 66.00 Cr..

Notably, the Reserves (348.00 Cr.) exceed the Borrowings (115.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +141542599034634311610541
Cash from Investing Activity +-25-18-137-101-97-44-41-26-55-16-0
Cash from Financing Activity +13110-128912-47-1-22-41-91-51
Net Cash Flow2-21-4476-5721-419-1-10

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-39.00-55.00-68.00-75.00-80.00-53.00-158.00-149.00-177.00-202.00-111.00-5.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

No data available for the Financial Efficiency data table.

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters59.58%59.58%59.58%59.58%59.58%59.58%62.06%62.06%62.06%62.06%62.06%62.06%
FIIs0.01%0.01%0.01%0.01%0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.05%
DIIs0.05%0.05%0.05%0.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public38.37%38.37%38.37%38.38%38.45%38.46%36.00%36.04%36.05%36.05%36.11%36.41%
Others1.98%1.98%1.98%1.98%1.95%1.95%1.92%1.89%1.89%1.89%1.82%1.47%
No. of Shareholders18,57817,51817,47217,97117,61016,89716,14815,72115,15015,17814,58913,221

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 26.35-7.99-17.855.3315.77
Diluted EPS (Rs.) 26.35-7.99-17.855.3315.69
Cash EPS (Rs.) 34.500.24-8.7714.0821.78
Book Value[Excl.RevalReserv]/Share (Rs.) 122.9198.76108.08128.76124.90
Book Value[Incl.RevalReserv]/Share (Rs.) 122.9198.76108.08128.76124.90
Revenue From Operations / Share (Rs.) 160.95116.25121.27138.15130.79
PBDIT / Share (Rs.) 41.6913.628.8824.1231.17
PBIT / Share (Rs.) 33.395.06-0.9015.2624.13
PBT / Share (Rs.) 28.53-3.42-17.989.3417.90
Net Profit / Share (Rs.) 26.19-8.31-18.565.2214.74
NP After MI And SOA / Share (Rs.) 26.35-7.99-17.855.3515.77
PBDIT Margin (%) 25.9011.717.3217.4623.83
PBIT Margin (%) 20.744.34-0.7411.0418.44
PBT Margin (%) 17.72-2.94-14.826.7613.68
Net Profit Margin (%) 16.27-7.15-15.303.7711.27
NP After MI And SOA Margin (%) 16.37-6.86-14.713.8712.06
Return on Networth / Equity (%) 21.43-7.98-16.364.1512.62
Return on Capital Employeed (%) 24.193.89-0.618.8114.56
Return On Assets (%) 12.50-4.20-8.092.186.62
Long Term Debt / Equity (X) 0.040.140.260.300.30
Total Debt / Equity (X) 0.300.450.680.630.57
Asset Turnover Ratio (%) 0.800.560.520.550.57
Current Ratio (X) 1.581.401.211.521.48
Quick Ratio (X) 0.990.890.580.740.70
Inventory Turnover Ratio (X) 1.130.700.770.911.06
Dividend Payout Ratio (NP) (%) 0.00-15.65-7.0046.680.00
Dividend Payout Ratio (CP) (%) 0.00217.49-15.5017.580.00
Earning Retention Ratio (%) 0.00115.65107.0053.320.00
Cash Earning Retention Ratio (%) 0.00-117.49115.5082.420.00
Interest Coverage Ratio (X) 8.572.311.234.075.00
Interest Coverage Ratio (Post Tax) (X) 6.380.02-0.201.883.37
Enterprise Value (Cr.) 835.62505.89464.45795.24883.96
EV / Net Operating Revenue (X) 1.781.511.332.002.34
EV / EBITDA (X) 6.8712.8718.1211.439.83
MarketCap / Net Operating Revenue (X) 1.701.300.881.491.91
Retention Ratios (%) 0.00115.65107.0053.310.00
Price / BV (X) 2.231.510.981.592.00
Price / Net Operating Revenue (X) 1.701.300.881.491.91
EarningsYield 0.09-0.05-0.160.020.06

After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
  • For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 122.91. It has increased from 98.76 (Mar 24) to 122.91, marking an increase of 24.15.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 122.91. It has increased from 98.76 (Mar 24) to 122.91, marking an increase of 24.15.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
  • For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
  • For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
  • For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
  • For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
  • For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 21.43. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.43, marking an increase of 29.41.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
  • For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
  • For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
  • For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 4. It has increased from 0.70 (Mar 24) to 1.13, marking an increase of 0.43.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 0.00, marking an increase of 15.65.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 0.00, marking a decrease of 217.49.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 115.65 (Mar 24) to 0.00, marking a decrease of 115.65.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -117.49 (Mar 24) to 0.00, marking an increase of 117.49.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 835.62. It has increased from 505.89 (Mar 24) to 835.62, marking an increase of 329.73.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.78, marking an increase of 0.27.
  • For EV / EBITDA (X), as of Mar 25, the value is 6.87. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.87, marking a decrease of 6.00.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
  • For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 115.65 (Mar 24) to 0.00, marking a decrease of 115.65.
  • For Price / BV (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.23, marking an increase of 0.72.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
  • For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Fermenta Biotech Ltd as of August 5, 2025 is: 323.04

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of August 5, 2025, Fermenta Biotech Ltd is Overvalued by 10.76% compared to the current share price 362.00

Intrinsic Value of Fermenta Biotech Ltd as of August 5, 2025 is: 358.76

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of August 5, 2025, Fermenta Biotech Ltd is Overvalued by 0.90% compared to the current share price 362.00

Last 5 Year EPS CAGR: 11.06%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
    1. Net Profit Margin: 16.27%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 24.19% (Industry Average ROCE: 16.63%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 21.43% (Industry Average ROE: 15.27%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 6.38
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.99
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 13.2 (Industry average Stock P/E: 53.48)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.3
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Fermenta Biotech Ltd. is a Public Limited Listed company incorporated on 01/05/1951 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1951PLC008485 and registration number is 008485. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 430.53 Cr. and Equity Capital is Rs. 14.58 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsA-1501, Thane One, DIL Complex, Thane Maharashtra 400610info@fermentabiotech.com
https://www.fermentabiotech.com
Management
NamePosition Held
Mr. Pradeep M ChandanChairman & Ind.Dire (Non-Exe)
Mr. Krishna DatlaExe.Vice Chairman & Whole Time Director
Mr. Prashant NagreManaging Director
Mr. Satish VarmaExecutive Director
Ms. Anupama Datla DesaiExecutive Director
Ms. Rajeshwari DatlaNon Executive Director
Mr. Pramod KasatInd. Non-Executive Director
Ms. Rajashri OjhaInd. Non-Executive Director
Mr. Ramanand MundkurIndependent Director

FAQ

What is the intrinsic value of Fermenta Biotech Ltd?

Fermenta Biotech Ltd's intrinsic value (as of 05 August 2025) is ₹323.04 which is 10.76% lower the current market price of ₹362.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,065 Cr. market cap, FY2025-2026 high/low of 449/219, reserves of 348 Cr, and liabilities of 614 Cr.

What is the Market Cap of Fermenta Biotech Ltd?

The Market Cap of Fermenta Biotech Ltd is 1,065 Cr..

What is the current Stock Price of Fermenta Biotech Ltd as on 05 August 2025?

The current stock price of Fermenta Biotech Ltd as on 05 August 2025 is 362.

What is the High / Low of Fermenta Biotech Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Fermenta Biotech Ltd stocks is ₹449/219.

What is the Stock P/E of Fermenta Biotech Ltd?

The Stock P/E of Fermenta Biotech Ltd is 13.2.

What is the Book Value of Fermenta Biotech Ltd?

The Book Value of Fermenta Biotech Ltd is 123.

What is the Dividend Yield of Fermenta Biotech Ltd?

The Dividend Yield of Fermenta Biotech Ltd is 0.69 %.

What is the ROCE of Fermenta Biotech Ltd?

The ROCE of Fermenta Biotech Ltd is 23.0 %.

What is the ROE of Fermenta Biotech Ltd?

The ROE of Fermenta Biotech Ltd is 24.7 %.

What is the Face Value of Fermenta Biotech Ltd?

The Face Value of Fermenta Biotech Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Fermenta Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE